Browsing by Author "Mamis, Edgars"

Now showing 1 - 6 of 6
  • No Thumbnail Available
    Item
    Accuracy of 68Ga-PSMA-11 PET/CT and multiparametric MRI for the detection of local tumor and lymph node metastases in early biochemical recurrence of prostate cancer
    (2020) Radzina, Maija; Tirane, Mara; Roznere, Lilita; Zemniece, Liene; Dronka, Laura; Kalnina, Marika; Mamis, Edgars; Biederer, Juergen; Lietuvietis, Vilnis; Freimanis, Arvis; Vjaters, Egils; Department of Radiology
    Anatomical and functional imaging plays a decisive role for detection and staging, of prostate cancer both primarily and post-treatment. While multiparametric MRI offers anatomic imaging with excellent soft tissue contrast, hybrid imaging based on positron emission tomography in combination with computed tomography (PET/CT) contributes functional imaging capacities. Since 68Ga-PSMA-11 was expected to be more efficient than the prior Choline-based PET radiotracers, it was the aim of the study to evaluate the diagnostic performance of the 68Ga-PSMA-11 PET/CT and multiparametric MRI in patients with recurrent prostate cancer and low PSA levels. 32 out of a cohort of 128 prostate cancer patients with biochemical relapse were referred for 68Ga-PSMA-11 PET/CT, MRI and bone scintigraphy. According to the histopathologically or clinically defined reference standard all results were classified as true positive, false positive, true negative or false negative. Local recurrence was present in 11/32 patients, lymph node metastases - in 13/32 patients and, bone metastases - in 6/32 patients. Against the standard of reference, sensitivity, specificity and accuracy for local recurrence of PET/CT were 63.6 %; 73.7%; 77.8%, respectively. MRI reached 90.9%; 94.7%; 92.3%, respectively. For local lymph node metastases PET/CT - 83.3%; 80.0% and 90.6%, respectively. MRI - 41.7%; 94.4%; 72.0%, respectively. For evaluation of bone metastases in PET/CT - 83.3%; 92.0%; 71.0%, respectively. Bone scintigraphy - 50.0%; 84.0%; 77.4%, respectively. In conclusion, mpMRI offered the better diagnostic accuracy in the detection of local recurrence and while PSMA PET/CT was superior in the detection of distant and lymph node metastases.
  • No Thumbnail Available
    Item
    Deliverable 5.1 - Questionnaire on industrial and clinical key players and needs (v1.0).
    (2022-09-30) Radzina, Maija; Mamis, Edgars; Saule, Laura; Pajuste, Elīna; Kalniņa, Marika; Cocolios, Thomas; Talip, Zeynep; Stora, Thierry
    This document is a summary of responses received from the public known European industrial manufacturing and research institution and clinical facility representatives. The responses were given to the PRISMAP Consortium questionnaire disseminated in January-August 2022, approaching radionuclides and radiopharmaceutical manufacturers, research institutions and clinical end users in nuclear medicine, with the aim to identify potential stakeholders in the industrial and clinical communities interested by a coordinated approach in Europe such as PRISMAP. The summary from PRISMAP questionnaire stratifies the feedback from 114 respondents: radionuclide and radiopharmaceutical producers, research facilities and preclinical/clinical end users. In addition, it gives an insight into the location and capabilities of the main isotope-producing cyclotron facilities, many of which are known from the IAEA cyclotron database [2]). The questionnaire was offered with an opportunity to make new research and international collaboration partners, where all parties could benefit from harmonised supply and legislation procedures, expanding network and distribution routes, and subsequently gain visibility within the PRISMAP User Forum map at www.prismap.eu. The questionnaire was focused on the radionuclide use in medicine with emphasis on future needs for specific radionuclides and possible research developments with awareness of legislation, logistics and involved personnel education challenges and future perspectives.
  • No Thumbnail Available
    Item
    Diagnostic scope of 18 F-PSMA-1007 PET/CT : comparison with multiparametric MRI and bone scintigraphy for the assessment of early prostate cancer recurrence
    (2021-10-15) Saule, Laura; Radzina, Maija; Liepa, Māra; Roznere, Lilita; Kalnina, Marika; Lioznovs, Andrejs; Mamis, Edgars; Mikelsone, Madara; Biederer, Juergen; Vjaters, Egils; Department of Radiology; Rīga Stradiņš University; Statistics Unit; Onkoloģijas institūts
  • No Thumbnail Available
    Item
    Novel radionuclides for use in Nuclear Medicine in Europe : where do we stand and where do we go?
    (2023-12) Radzina, Maija; Saule, Laura; Mamis, Edgars; Koester, Ulli; Cocolios, Thomas Elias; Pajuste, Elina; Kalnina, Marika; Palskis, Kristaps; Sawitzki, Zoe; Talip, Zeynep; Jensen, Mikael; Duchemin, Charlotte; Leufgen, Kirsten; Stora, Thierry; Rīga Stradiņš University
    BACKGROUND: In order to support the ongoing research across Europe to facilitate access to novel radionuclides, the PRISMAP consortium (European medical radionuclides programme) was established to offer the broadest catalog of non-conventional radionuclides for medical and translational research. The aim of this article is to introduce readers with current status of novel radionuclides in Europe. MAIN BODY: A consortium questionnaire was disseminated through the PRISMAP consortium and user community, professional associations and preclinical/clinical end users in Europe and the current status of clinical end-users in nuclear medicine were identified. A total of 40 preclinical/clinical users institutions took part in the survey. Clinical end users currently use the following radionuclides in their studies: 177Lu, 68 Ga, 111In, 90Y, other alpha emitters, 225Ac, 64Cu and Terbium isotopes. Radionuclides that would be of interest for users within the next 2-5 years are 64Cu, Terbium radionuclide "family" and alpha emitters, such as 225Ac. CONCLUSIONS: Thanks to a questionnaire distributed by the PRISMAP consortium, the current status and needs of clinical end-users in nuclear medicine were identified.
  • No Thumbnail Available
    Item
    “Particle therapy - future for the Baltic states?” – synthesis of the expert workshop report
    (2024-09) Paļskis, Kristaps; Korobeinikova, Erika; Bogorada-Saukuma, Dace; Camarda, Anna Maria; Taylor, Rebecca; Benedetto, Elena; Mamis, Edgars; Radziņa, Maija; Ērglis, Andrejs; Adliene, Diana; Dosanjh, Manjit; Vretenar, Maurizio; Torims, Toms; Rīga Stradiņš University
    Background: Baltic States remains one of the few regions in the Europe without a dedicated particle therapy center. An initiative since 2021 has been started by CERN Baltic Group on a novel particle therapy center development in the region in partnership with CERN NIMMS collaboration. With a conceptual design idea in early 2022 and stakeholder engagement activities in late 2022 - next step forward was necessary for the initiative for a more in-depth analysis. Methods: A dedicated workshop “Particle therapy - future for the Baltic States? State-of-play, synergies and challenges” was held. The workshop was attended by medical community from the Baltics, as well as CERN technical experts and particle therapy practicing clinicians, with scientific programme split in 5 main areas of investigation. Results: Current cancer epidemiology statistics and RT technological possibilities in the region were analyzed, with first estimates of eligible number of patients calculated. Technological development level of the proposed accelerator complex was discussed, as well the clinical needs and synnergy possibilities with the nuclear medicine field. Conclusions: The current state and calculated first estimates presented here have shown a promising starting point, which prompts even further in-depth work – a feasibility study for development of a novel particle therapy center in the Baltic States.
  • No Thumbnail Available
    Item
    Recurrent Prostate Cancer Diagnostics with 18F-PSMA-1007 PET/CT: A Systematic Review of the Current State
    (2022-12-15) Saule, Laura; Radzina, Maija; Liepa, Mara; Roznere, Lilita; Lioznovs, Andrejs; Ratniece, Madara; Mamis, Edgars; Vjaters, Egils; Department of Radiology
    BACKGROUND: Early diagnosis of recurrent prostate cancer is a cornerstone for further adequate therapy planning. Therefore, clinical practice and research still focuses on diagnostic tools that can detect prostate cancer in early recurrence when it is undetectable in conventional diagnostic imaging. 18F-PSMA-1007 PET/CT is a novel method to evaluate patients with biochemical recurrent PCa. The aim of this review was to evaluate the role of 18F-PSMA-1007 PET/CT in prostate cancer local recurrence, lymph node metastases and bone metastases detection. METHODS: Original studies, reviews and five meta-analyses were included in this article. A total of 70 studies were retrieved, 31 were included in the study. RESULTS: All patients described in the studies underwent 18F-PSMA-1007 PET/CT. The administered 18F-PSMA-1007 individual dose ranged from 159 ± 31 MBq to 363.93 ± 69.40 MBq. Results showed that 18F-PSMA-1007 PET/CT demonstrates a good detection rate in recurrent prostate cancer. CONCLUSIONS: 18F-PSMA-1007 PET/CT appears to achieve reliable performance in detecting recurrent prostate cancer. The high detection rate of 18F-PSMA-1007 PET/CT in recurrent prostate cancer was confirmed, especially in local recurrence and small lymph nodes with non-specific characteristics on conventional diagnostic imaging methods. However, several authors emphasize some limitations for this tracer-for example, non-specific uptake in bone lesions that can mimic bone metastases.